Renamed Perseon Corporation in c. 2015, BSD Medical Corporation (NASDAQ) had been organized around treatment of cancer and benign diseases through heat therapy delivered using focused radiofrequency (RF) and microwave energy. Shortly thereafter that name change, the firm was acquired by Galil Corporation an Israeli developer of oncology cryoablation technology. Developing technology and products for thermal ablation and hyperthermia cancer therapy through various techniques, to include thermal ablation that ablates soft tissues at high temperatures through focused microwave energy; and superficial hyperthermia, which non-invasively treats cancerous tumors located within a few centimeters of the surface of the body, including melanoma and recurrent breast cancer, the company also developed internal or interstitial hyperthermia that treats tumors in combination with internal radiation therapy; and deep hyperthermia, which non-invasively treats tumors located deep within the body. It provides MicroThermX microwave ablation systems for the ablation of soft tissue; BSD-500 Hyperthermia System that delivers superficial or interstitial hyperthermia therapy or both; and BSD-2000 Hyperthermia System, which non-invasively delivers localized therapeutic heating to solid tumors by applying RF energy to certain cancerous tumors, as well as BSD-2000/3D and BSD-2000/3D/MR systems. The company serves clinics, hospitals, and institutes in the United States and internationally.